Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Roivant buys computational physics firm Silicon Therapeutics

by Megha Satyanarayana
March 5, 2021 | A version of this story appeared in Volume 99, Issue 8

 

Roivant Sciences is buying Silicon Therapeutics for $450 million in Roivant stock. Silicon Therapeutics uses computational physics to predict thermodynamics and conformational behavior of complex drug targets, with the goal of developing small-molecule modulators of those targets. Roivant says it will use Silicon Therapeutics’ technology to augment its technology for targeted protein degradation and to develop allosteric inhibitors, molecular glues, and high-affinity ligands.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.